Literature DB >> 2297197

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy.

G E Marais1, K K Larson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297197     DOI: 10.7326/0003-4819-112-3-228

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  11 in total

1.  Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine.

Authors:  C Chrysanthopoulos; N Kounis
Journal:  BMJ       Date:  1992-05-09

2.  Myopathic effects of lovastatin.

Authors:  W N Suki
Journal:  West J Med       Date:  1991-02

Review 3.  Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case.

Authors:  T K Lau; D R Leachman; R Lufschanowski
Journal:  Tex Heart Inst J       Date:  2001

4.  Lovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exercise.

Authors:  C S Reust; S C Curry; J R Guidry
Journal:  West J Med       Date:  1991-02

Review 5.  Drug interactions of lipid-altering drugs.

Authors:  H E Bays; C A Dujovne
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

6.  The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.

Authors:  G Feussner; M Eichinger; R Ziegler
Journal:  Clin Investig       Date:  1992-11

Review 7.  Clinical pharmacokinetics and practical applications of simvastatin.

Authors:  V F Mauro
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

8.  Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.

Authors:  M D Feher; J Foxton; D Banks; A F Lant; R Wray
Journal:  Br Heart J       Date:  1995-07

Review 9.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

Review 10.  Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.

Authors:  C M Spencer; L B Barradell
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.